Katherine Hutcheson
UT MD Anderson
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Katherine Hutcheson as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:01 UTC. Open this list on ClinicalTrials.gov
- Ph1NCT07832266 · Proactively Intervening On Early Cranial Nerve Injury As A Delayed Sequela Of Oropharyngeal Cancer: A Randomized Feasibility Clinical Trial For Pro-Habilitation (proNERVE RCT)M.D. Anderson Cancer Center · not yet recruiting · Cranial Nerve Injury, Oropharyngeal Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:01 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Core A: AdministrativeP01CA285249 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2024 to 2026 · $212,612 awarded in 2026Same name and institution; not confirmed by an ID
- Dissemination and implementation of DIGEST™ as an evidence-based measurement tool for dysphagia in cancerR01CA271223 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2023 to 2026 · $632,834 awarded in 2026Same name and institution; not confirmed by an ID
- Harvard MD Anderson Collaborative to Reduce LyMphatic MOrbidity in Head and Neck Cancer with Artificial Intelligence (HARMONiC-AI)R01DE034780 · NIDCR · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2025 to 2026 · $716,638 awarded in 2026Same name and institution; not confirmed by an ID
- Project 2: InHANCE: Radiation Associated DysphagiaP01CA278716 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2025 to 2026 · $477,737 awarded in 2026Same name and institution; not confirmed by an ID
- Hypoglossal neuropathy in the pathogenesis of radiation associated dysphagia (hRAD)R21CA273984 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2023 to 2024 · $196,648 awarded in 2024Same name and institution; not confirmed by an ID
- imaging Radiation-Associated Dysphagia (iRAD)R01CA218148 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2017 to 2019 · $217,667 awarded in 2019Same name and institution; not confirmed by an ID
- Manual Therapy for Fibrosis-related Late Effect Dysphagia in Head and Neck Cancer Survivors: The MANTLE TrialR21CA226200 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2018 to 2019 · $168,779 awarded in 2019Same name and institution; not confirmed by an ID
- Lingual Strength & Dysphagia after Oropharynx Cancer: Proton vs. Photon RadiationR03CA188162 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · fiscal years 2015 to 2016 · $80,000 awarded in 2016Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:01 UTC. The ranking covers the 200 most relevant of 19 PubMed records, and a shared surname and initials can bring in a namesake. All 19 on PubMed
- 236 citationsRCR 9.3
- Candidate dosimetric predictors of long-term swallowing dysfunction after oropharyngeal intensity-modulated radiotherapy.Int J Radiat Oncol Biol Phys · 2010149 citationsRCR 5.4
- Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results.Clin Cancer Res · 2020117 citationsRCR 4.1
- Long-Term, Prospective Performance of the MD Anderson Dysphagia Inventory in "Low-Intermediate Risk" Oropharyngeal Carcinoma After Intensity Modulated Radiation Therapy.Int J Radiat Oncol Biol Phys · 201755 citationsRCR 2.8
- 46 citationsRCR 1.5
- 46 citationsRCR 23.1
- 37 citationsRCR 1.6
- 22 citationsRCR 0.9
- Manual Therapy for Fibrosis-Related Late Effect Dysphagia in head and neck cancer survivors: the pilot MANTLE trial.BMJ Open · 202122 citationsRCR 2.2
- Effect of induction chemotherapy on speech and swallowing function in patients with oral tongue cancer.Head Neck · 200917 citationsRCR 0.7